CA2297988A1 - Inhibiteurs de metalloproteases heterocycliques hybrides et substitues par de l'acide hydroxamique - Google Patents

Inhibiteurs de metalloproteases heterocycliques hybrides et substitues par de l'acide hydroxamique Download PDF

Info

Publication number
CA2297988A1
CA2297988A1 CA002297988A CA2297988A CA2297988A1 CA 2297988 A1 CA2297988 A1 CA 2297988A1 CA 002297988 A CA002297988 A CA 002297988A CA 2297988 A CA2297988 A CA 2297988A CA 2297988 A1 CA2297988 A1 CA 2297988A1
Authority
CA
Canada
Prior art keywords
radicals
alkyl
radical
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002297988A
Other languages
English (en)
Inventor
Chan Kou Hwang
Kevin Koch
Sandra E. Russo-Rodriguez
Conrad Hummel
David S. Thomson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2297988A1 publication Critical patent/CA2297988A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Cette invention concerne de nouveaux composés hétérocycliques hybrides et substitués par de l'acide hydroxamique qui correspondent à la formule (I) et sont efficaces pour la prophylaxie et le traitement d'inflammations, de la dégradation tissulaire et des affections apparentées. Cette invention concerne de nouveaux composés, des analogues, des promédicaments et leurs sels pharmaceutiquement acceptables, des compositions pharmaceutiques ainsi que des procédés pour la prophylaxie et le traitement d'inflammations, de la dégradation tissulaire et des affections apparentées. L'invention se rapporte également à des processus permettant d'obtenir ces composés ainsi qu'à des produits intermédiaires utiles dans ces processus (I).
CA002297988A 1997-08-04 1998-08-04 Inhibiteurs de metalloproteases heterocycliques hybrides et substitues par de l'acide hydroxamique Abandoned CA2297988A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5475397P 1997-08-04 1997-08-04
US60/054,753 1997-08-04
US12851298A 1998-08-03 1998-08-03
US09/128,512 1998-08-03
PCT/US1998/016147 WO1999006410A1 (fr) 1997-08-04 1998-08-04 Inhibiteurs de metalloproteases heterocycliques hybrides et substitues par de l'acide hydroxamique

Publications (1)

Publication Number Publication Date
CA2297988A1 true CA2297988A1 (fr) 1999-02-11

Family

ID=26733456

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002297988A Abandoned CA2297988A1 (fr) 1997-08-04 1998-08-04 Inhibiteurs de metalloproteases heterocycliques hybrides et substitues par de l'acide hydroxamique

Country Status (5)

Country Link
EP (1) EP1003751A1 (fr)
JP (1) JP2003524572A (fr)
AU (1) AU8766498A (fr)
CA (1) CA2297988A1 (fr)
WO (1) WO1999006410A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023443A1 (fr) * 1998-10-22 2000-04-27 Akzo Nobel N.V. Derives de tetrahydropyridopyridine, et produits intermediaires permettant de produire lesdits derives
FR2795730B1 (fr) * 1999-07-01 2001-08-31 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1219607B1 (fr) * 1999-09-02 2011-04-06 Shionogi & Co., Ltd. Inhibiteur d'integrase contenant des derives heterocycliques aromatiques
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
DK2270052T3 (en) 2001-06-26 2018-07-02 Amgen Inc Antibodies to OPGL
KR20060052867A (ko) * 2003-07-23 2006-05-19 엑셀리시스, 인코포레이티드 약제로서의 아제핀 유도체
DE102004004974A1 (de) * 2004-01-31 2005-08-18 Aventis Pharma Deutschland Gmbh Thieno-Iminosäure-Derivate als Inhibitoren von Matrix-Metalloproteinasen
DE102005002500A1 (de) 2005-01-19 2006-07-27 Sanofi-Aventis Deutschland Gmbh Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen
SG121932A1 (en) * 2005-07-27 2006-05-26 Takenaka Corp Mobile building platform
NZ584279A (en) 2007-09-19 2011-11-25 4Sc Ag Novel tetrahydrofusedpyridines as histone deacetylase inhibitors
EP2318361B1 (fr) * 2008-07-14 2015-09-23 Novartis AG Inhibiteurs sélectifs de mmp-12 et mmp-13 à base d acide hydroxamique
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
AU2019352741A1 (en) 2018-10-04 2021-05-06 Assistance Publique-Hôpitaux De Paris (Aphp) EGFR inhibitors for treating keratodermas
CN113387959B (zh) * 2021-06-24 2023-05-05 烟台理工学院 一种噻吩并[3,2-c]吡啶-6-羧酸甲酯的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100475206B1 (ko) * 1995-11-13 2005-12-16 훽스트 악티엔게젤샤프트 사이클릭및헤테로사이클릭N-치환된α-이미노하이드록삼산및카복실산
FR2748026B1 (fr) * 1996-04-26 1998-06-05 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
EP1003751A1 (fr) 2000-05-31
JP2003524572A (ja) 2003-08-19
AU8766498A (en) 1999-02-22
WO1999006410A1 (fr) 1999-02-11

Similar Documents

Publication Publication Date Title
CA2297988A1 (fr) Inhibiteurs de metalloproteases heterocycliques hybrides et substitues par de l'acide hydroxamique
EP0991653B1 (fr) Nouveaux composes
CA1328262C (fr) Sulfonamides aromatiques substitues en tant qu'agents anti-glaucomateux
AU2003292828B2 (en) Diamine derivatives
AU2002346300B2 (en) Diamine derivatives
RU2268259C2 (ru) ПРОИЗВОДНЫЕ ЭТИЛЕНДИАМИНА И СОДЕРЖАЩИЕ ИХ ИНГИБИТОР FXa И АНТИКОАГУЛЯНТ
AU2002328596B2 (en) Diamine derivatives
CA2504385C (fr) Agents anti-infectieux
JP5579724B2 (ja) ホスファチジルイノシトール−３−キナーゼ（ｐｉ−３キナーゼ）阻害剤としてのテトラ−アザ−複素環
DE602004008945T2 (de) Thienopyrrole als antivirale mittel
EP1778243B1 (fr) Derives d'azepine substitues utilises comme modulateurs des recepteurs de la serotonine
US20010020030A1 (en) Cell adhesion-inhibiting antiinflammatory compounds
JP2002517396A (ja) 細胞接着阻害抗炎症性化合物
CA2314154C (fr) Derives d'azepine et leur utilisation comme produits pharmaceutiques
OA11062A (en) Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
CA1182458A (fr) Derives de 5,6,7,7a-tetrahydro-4h-thieno-¬3,2-c) pyridin-2-one; preparation et applications
CA1336431C (fr) Composes de thiazolo(5,4-b)azepine
IE911192A1 (en) Substituted aromatic sulfonamides as antiglaucoma agents
US6984644B2 (en) Treatment of skin disorders using thieno[2,3-D]pyrimidinediones
WO2004052288A2 (fr) 2-nh-heteroarylimidazoles a activite antibacterienne
US20020183337A1 (en) Novel compounds
MXPA00006073A (en) Azepine or larger medium ring derivatives and their use as pharmaceuticals
MX2011003966A (es) Tieno[2,3-d]pirimidina sustituida con heteroarilo y su uso como antagonistas de receptores de adenosina a2a.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead